GRAIL, Inc. (NASDAQ:GRAL) is spotlighted by Jim Cramer for its cancer-detecting blood test. The company raised $325 million through a private placement after stock surge. Cramer warns of losses and advises caution despite a 347% increase this year. Stock is now at $79 from $103.

GRAL develops blood-based tests for early cancer detection, including the Galleri screening test. Cramer expresses bearish sentiment, referencing Dr. Topol’s negative view on the stock’s parabolic move. He advises against owning GRAL due to recent price surge.

For investors seeking AI stocks, GRAL offers potential but with high risk. Other AI stocks may offer greater upside with less downside risk. A free report on the best short-term AI stock is available for those looking for undervalued opportunities. No specific recommendations are made in the article.

Read more at Yahoo Finance: “Don’t Call Yourself Early if You’re Buying This One”